The Top 5 Biosimilars Articles for the Week of February 24

Article

The Center for Biosimilars® recaps the top stories for the week of February 24, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 24, 2020.

Number 5: A new review analyzing the risk of cancer in patients with psoriasis found no increased risk for those treated with biologics.

Number 4: The FDA amends the definition of “biological product” in its final rule regarding the regulatory shift that begins March 23, when insulin and other biological products shift to a different approval pathway.

Number 3: A year-in-review article outlines 2019 studies about nonmedical switching and finds evidence to support moving from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

Number 2: AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira sales decline and more adalimumab biosimilars to the blockbuster arthritis drug enter international markets.

Number 1: The launch of Pfizer’s trastuzumab biosimilar, Trazimera, means the originator product Herceptin now has 3 biosimilar competitors.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Related Content
© 2023 MJH Life Sciences

All rights reserved.